Berzosertib deprives cancer cells of the immune system
Surprisingly positive results in the treatment of advanced tumors were achieved in a recent study using a drug from a new drug class. The substance called “Berzosertib” disabled specifically the repair of DNA damage in cancer cells, whereupon they die off. In the case of each of the second Participants of the study, the cancer growth could be stopped completely.
Researchers from the Institute of Cancer Research in London prior to the new cancer drug Berzosertib. In the first human clinical trials in the Mediterranean already showed amazing results. So Berzosertib had, for example, in the case of cancer Sufferers, have failed multiple chemotherapy regimens. Because the active ingredient is pursuing a completely new approach to kill cancer cells. The results of the study were recently presented in the “Journal of Clinical Oncology”.
Active ingredient converts starch into weakness
The damage to the DNA in the cells is the main cause for cancer. As a result, the cells multiply uncontrollably and grow into healthy tissue. Cancer cells, however, are more dependent than healthy cells on the ability to repair more occurring DNA damage. Without this capability you will die quickly. The new active ingredient is exactly at this point and robs the cancer cells of the vital capacity.
Every second, Participants stopped the growth
Berzosertib has now been tested for the first time on people, and gives surprisingly good results. Among 40 Participants with advanced forms of cancer could be stopped in half of the Affected cancer growth through the new drug. Two people talked exceptionally well to the treatment.
The cancer disappeared in some of the Participating
A Patient with advanced colorectal cancer whose Tumor contained error in important DNA repair genes, in language remarkably well to the sole administration of Berzosertib. His tumors were in the course of treatment and eventually disappeared entirely. The man is free to live now for the past two years, cancer.
In a further patient with advanced ovarian cancer, seven different chemo had failed therapies. She received treatment with Berzosertib, which was supplemented by Carboplatin treatment. Carboplatin inhibits the growth of cells and seems to support the effect of Berzosertib. As a result of the treatment, the Tumor began to shrink.
New family of targeted cancer drugs
“Our new clinical study is the first to test the security of a brand new family of targeted cancer drugs in humans, and it is encouraging to see already in this early stage, some clinical reactions,” explains Professor Johann de Bono from the study team.
“In the future, this new class of ATR could increase-inhibiting drugs is the effect of cancer treatments such as chemotherapy, our range of treatment options and resistance to other targeted treatments to overcome,” says the Professor. In other clinical studies, the effect of Berzosertib in combination with other drugs, the ATR should be block-proteins tested. (vb)